Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Gastroenterologists typically assess fecal calprotectin, endoscopic findings, and symptom severity to establish a clear baseline
You'll receive clear instructions on how to take it, and your care doesn't stop there
Be cautious of telehealth platforms that skip medical evaluation or promise rapid delivery without verifying your identity or health status
A JNK-dependent pathway is required for TNFa-induced apoptosis
For more information, please contact our customer support team at [email protected] or 1 (866) 910-1567
For the OSA indication, separate criteria apply: Polysomnography documenting moderate-to-severe OSA (typically AHI 15+) BMI 30 or higher CPAP intolerance, insufficiency, or contraindication documentation Sleep medicine physician co-signature in some plans The December 2024 OSA pathway The FDA's December 2024 approval of tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials (Malhotra et al., New England Journal of Medicine 2024), created a new coverage pathway
US$ 21.89
US$ 29.67
US$ 24.90
US$ 28.88
US$ 23.19
US$ 29.85
US$ 27.81
US$ 27.96
